Timeline Start of joint research/development within 1 year
Financials Details open to negotiation based on proposals
How to Apply
Click "Respond", complete the form to the extent possible, and submit along with other attachment files available.
After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.
If you have any questions or request, please feel free to contact us at : email@example.com
RFP was closed on
Transfer/Release to Vascular Tissue Technology
NineSigma, representing a Japanese medical device manufacturer (“Client”), seeks technology to quickly transfer drug from balloon to vascular tissue and sustain release for a long time.
The Client desires to develop a drug-coated balloon (DCB) by combining their proprietary technology with proposed technology. The challenge is, however, to transfer the drug into the vascular tissue in a short time and retain and elute it for an extended time. Therefore,the Client wants to develop a new DCB by combining drugs and drug delivery system (DDS) technology that meet the following requirements:
Figure. Conceptual diagram of DCB under consideration of development
Characteristics of drug to be used
Molecular weight: approx. 1000
Physical property: hydrophobic
The aforementioned drug is to be the first target of DCB development, but the Client intends to try several other drugs in the future.
Key Success Criteria
The Client seeks DDS technologies that meet the following requirements:
Targeted vascular sites:
Blood vessels in femoral-popliteal area
Blood vessels below knee
Administration method: Coat the balloon of the balloon catheter with the drug and transfer to targeted vascular sites mentioned above
Fast and high transferability into vascular tissue
Transfer time: ≤3 min
Transfer rate: Desirably, ≥80 % in the future
Desirable to keep eluting the drug for more than 6 months after the transfer
The Client expects technologies such as the following approaches, but is open to others as long as the aforementioned technological requirements can be met:
Technology that encapsulates the drug in microparticles or nanoparticles, coats the balloon with particles, and make particles be quickly absorbed into the inner lining of a blood vessel
Approaches not of Interest
Approaches Not of Interest
The following approaches are not of interest:
Technology that keeps intravitally irresolvable material inside a blood vessel for a long time, such as metallic stent
Items to be Submitted
Notes on Response
Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.
The client will evaluate all responses with the following criteria.
Overall scientific and technical merit
Approach to proof of concept or performance
Economic potential of concept
Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)
Potential for proprietary position
Respondents’ capability and related experiences
Anticipated Project Process
After the submission due date, the client will review all submitted proposals. NineSigma will send the review results to each proposer 6-8 weeks after the due date. The client possibly asks clarifying questions before selecting the most suitable candidates for collaboration. The client will select best candidates through evaluations. During the selection process, the client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities.
The client will execute necessary agreements with the selected respondents and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.